Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study
Authors:
- Kelly M. LoyetKLKelly M. Loyet
- Rong DengRDRong Deng
- Wei-Ching LiangWLWei-Ching Liang
- Yan WuYWYan Wu
- Henry B. LowmanHLHenry B. Lowman
- Laura E. DeForgeLDLaura E. DeForge
- 1 June 2009
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 345 (1-2) , 17-28
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsJournal of Immunological Methods, 2008
- Detection of High- and Low-Affinity Antibodies Against a Human Monoclonal Antibody Using Various Technology PlatformsASSAY and Drug Development Technologies, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeuticsJournal of Immunological Methods, 2007
- Immunogenicity, efficacy and adverse events of adalimumab in RA patientsRheumatology International, 2006
- A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selectionJournal of Immunological Methods, 2006
- Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic proteinJournal of Immunological Methods, 2006
- Antibody-mediated side effects of recombinant proteinsToxicology, 2005
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural ProbesHybridoma, 1987